RHR was independently associated with all-cause mortality, especially in lung and gastrointestinal cancers. Treatment-naïve cancer patients with higher RHRs display higher levels of cardiovascular biomarkers. In subgroup analyses, the strongest associations for RHR with mortality were observed in lung (crude HR 1.14 P = 0.007) and gastrointestinal (crude HR 1.31 P < 0.001) cancer. There was no significant impact of metastatic/non-metastatic disease state on the predictive value of RHR (P = 0.433 for interaction). In univariate survival analysis, RHR predicted all-cause mortality, and remained significantly associated with outcome after adjustment for age, gender, tumour entity, tumour stage, cardiac status and haemoglobin (adjusted HR for a 5 b.p.m. During a median follow-up of 25 months (interquartile range: 16-32 months range: 0-40 months), 185 (33.8%) patients died from any cause. Patients in the highest RHR tertile had higher levels of high-sensitivity troponin (P = 0.003) and N-terminal pro-B-type natriuretic peptide (P = 0.039). RHR was not related to cancer stage (P = 0.504). Clinical heart failure was noted in 37 (6.8%) patients. Most patients were in sinus rhythm (n = 507, 92.5%). The median age of the cohort was 62 years 40.9% were male and 32.7% had metastatic disease. This prospective study enrolled 548 unselected treatment-naïve cancer patients between 20. We aimed to establish whether RHR is associated with survival in treatment-naïve cancer patients. Elevated resting heart rate (RHR) has been identified as a marker for increased long-term mortality in cancer patients prior to the receipt of anticancer treatment. 7 Department of Entrepreneurship and Economic Education, Faculty of Business and Economics, Technical University Dortmund, Dortmund, Germany.Ĭancer patients suffer from impaired cardiovascular function. 6 Department of Integrated Safety and Security, University of Applied Sciences, FH Campus Vienna, Vienna, Austria.5 Department of Complexity Research, Complexity Science Hub, Vienna, Austria.4 Department of Internal Medicine I, Clinical Division of Oncology, Medical University of Vienna, Vienna, Austria.3 Department of Internal Medicine II, Clinical Division of Cardiology, Medical University of Vienna, Vienna, Austria.2 Department of Cardiology, Charité Universitätsmedizin Berlin (Campus CBF), Berlin, Germany.1 Department of Cardiology & Berlin Institute of Health Center for Regenerative Therapies (BCRT), German Center for Cardiovascular Research (DZHK), Partner Site Berlin, Charité-Universitätsmedizin Berlin (Campus CVK), Berlin, Germany.
0 Comments
Leave a Reply. |